Form 4 Filing for Enliven Therapeutics, Inc.

This filing details transactions by OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC, all of whom are significant beneficial owners of Enliven Therapeutics, Inc. (ELVN). On June 22, 2026, these entities reported the disposal of a total of 860,077 shares of Common Stock. Specifically, OrbiMed Genesis GP LLC disposed of 24,846 shares at $45.38 and 1,477 shares at $45.00. Concurrently, OrbiMed Capital GP VII LLC disposed of 787,024 shares at $45.38 and 46,776 shares at $45.00. These transactions are reported on Form 4, indicating changes in beneficial ownership. The reporting persons, through various entities, exercise voting and investment power over these securities but disclaim beneficial ownership beyond their pecuniary interest.